<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397956</url>
  </required_header>
  <id_info>
    <org_study_id>0826-053</org_study_id>
    <secondary_id>2006_047</secondary_id>
    <nct_id>NCT00397956</nct_id>
  </id_info>
  <brief_title>To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)</brief_title>
  <official_title>An Open-Label, Single-Arm, Non-Comparative Study to Evaluate the Efficacy, Tolerability &amp; Convenience of Invanz(TM) (Ertapenem Sodium) In the Treatment of Community-Acquired Sepsis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To collect clinical response data with the use of ertapenem in community acquired sepsis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Signs and symptoms of infection on days 3, 4, 7 and 14 during treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Sepsis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0826, ertapenem sodium / Duration of Treatment: 14 Days</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 18 years of age or older

          -  Patients present with at least two of the following signs and symptom:

          -  fever (temperature&gt; 38c or &lt; 36c)

          -  heart rate &gt; 90 beats/min)

          -  respiratory rate&gt; 20 breaths/min)

          -  high white blood cell count &gt; 12,000/ul or &gt;10% bands)

        Exclusion Criteria:

          -  Patient has a history of allergy or hypersensitivity (anaphylaxis) or serious adverse
             reaction to ertapenem or any carbapenem

          -  Patient has a poor chance of survival for more than 14 days.

          -  Patient has an apache ii score &gt; 15 (see attachment 3.

          -  Patient has an infection caused by pathogens resistant to ertapenem

          -  The patient requires antibiotics other than ertapenem (such as: glycopeptides,
             macrolides or antifungal agents)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>October 29, 2015</last_update_submitted>
  <last_update_submitted_qc>October 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

